Lyndra Inc
Watertown Massachusetts UNITED STATES
Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.
None yet.